{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T09:40:14.678188+00:00","company":{"ticker":"IMDX","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc."},"pagination":{"limit":100,"returned":11,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"b46d04e430cb560d3e0e898af7f88b46d369f815","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2026-02-26T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Specimen Collection Agreement","agreement_type":"supply","counterparty":"Quest Diagnostics Incorporated","effective_date":"2026-02-20","item_codes_triggered":["1.01"],"value_text":null},"claim":"Insight Molecular Diagnostics Inc. entered into Specimen Collection Agreement with Quest Diagnostics Incorporated (effective 2026-02-20).","evidence_excerpt":"On February 20, 2026, Insight Molecular Diagnostics Inc. (the “Company”) entered into a Specimen Collection Agreement (the “Agreement”) with Quest Diagnostics Incorporated (“Quest Diagnostics”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-008169","anchor_url":"https://secwatch.observer/filing/0001493152-26-008169#claim-b46d04e430cb560d3e0e898af7f88b46d369f815","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226008169/0001493152-26-008169-index.htm"},{"fact_type":"material_agreement","fact_key":"b029335648a8593a550bae6f80deee4e453e1148","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Placement Agency Agreement","agreement_type":"underwriting","counterparty":"Lake Street Capital Markets, LLC","effective_date":"2026-02-10","item_codes_triggered":["1.01"],"value_text":null},"claim":"Insight Molecular Diagnostics Inc. entered into Placement Agency Agreement with Lake Street Capital Markets, LLC (effective 2026-02-10).","evidence_excerpt":"The Company entered into a placement agency agreement (the “ Placement Agency Agreement ”), dated as of February 10, 2026, with Lake Street Capital Markets, LLC (the “ Placement Agent ”), pursuant to which the Placement Agent agreed to serve as the placement agent for the Company in connection with the Offering.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-006473","anchor_url":"https://secwatch.observer/filing/0001493152-26-006473#claim-b029335648a8593a550bae6f80deee4e453e1148","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm"},{"fact_type":"material_agreement","fact_key":"b04a86801415d4f69f1efba799b6fa8b1468d2f9","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2026-02-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreements","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2026-02-10","item_codes_triggered":["1.01"],"value_text":"approximately $24.5 million"},"claim":"Insight Molecular Diagnostics Inc. entered into Purchase Agreements with certain institutional investors valued at approximately $24.5 million (effective 2026-02-10).","evidence_excerpt":"On February 10, 2026, Insight Molecular Diagnostics Inc. (the “ Company ”) entered into securities purchase agreements (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to issue and sell (i) 3,482,498 shares (the “ Shares ”) of the Company’s common stock, no par value per share (the “ Common Stock ”), and (ii) Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase up to 1,043,478 shares of Common Stock (the “ Pre-Funded Warrant Shares ”) in a registered direct offering (the “ Offering ”), pursuant to an effective shelf registration statement on Form S-3 (File No. 333-281159), a base prospectus and prospectus supplement relating to the Offering (the “ Prospectus Supplement ”), in each case filed with the Securities and Exchange Commission.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-006473","anchor_url":"https://secwatch.observer/filing/0001493152-26-006473#claim-b04a86801415d4f69f1efba799b6fa8b1468d2f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226006473/0001493152-26-006473-index.htm"},{"fact_type":"governance_change","fact_key":"fb7e746e9b46d0fc3d52b8c29f8b2ac553f12545","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-06-17T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change."},"claim":"Insight Molecular Diagnostics Inc.: Amended and restated bylaws (Third Amended and Restated Bylaws) solely to reflect the company name change (effective 2025-06-13).","evidence_excerpt":"Also on June 13, 2025, the Company amended and restated the Company’s Second Amended and Restated Bylaws (the “Third Amended and Restated Bylaws”) solely to reflect the Name Change.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-015338","anchor_url":"https://secwatch.observer/filing/0001641172-25-015338#claim-fb7e746e9b46d0fc3d52b8c29f8b2ac553f12545","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm"},{"fact_type":"governance_change","fact_key":"4014a773c55f849ba1d8be0b6468de3c36636415","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-06-17T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-06-13","item_codes_triggered":["5.03"],"summary_text":"Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc."},"claim":"Insight Molecular Diagnostics Inc.: Amended Article I of Articles of Incorporation to change company name from Oncocyte Corporation to Insight Molecular Diagnostics Inc (effective 2025-06-13).","evidence_excerpt":"In connection with the Name Change, the Company filed a Certificate of Ownership with the Secretary of State of the State of California on June 13, 2025, to amend Article I of the Company’s Articles of Incorporation solely to reflect the Company’s new corporate name.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-015338","anchor_url":"https://secwatch.observer/filing/0001641172-25-015338#claim-4014a773c55f849ba1d8be0b6468de3c36636415","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225015338/0001641172-25-015338-index.htm"},{"fact_type":"executive_change","fact_key":"d71044abce","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2025-03-10T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2025-03-10","interim":false,"role":"Vice President Accounting, Controller, Treasurer and Principal Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"James Liu changed role as Vice President Accounting, Controller, Treasurer and Principal Accounting Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-25-009684","anchor_url":"https://secwatch.observer/filing/0001493152-25-009684#claim-d71044abce","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315225009684/0001493152-25-009684-index.htm"},{"fact_type":"executive_change","fact_key":"0866438761","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-06-17T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-17","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Andrea James was appointed as Chief Financial Officer at Insight Molecular Diagnostics Inc..","evidence_excerpt":"On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001493152-24-024108","anchor_url":"https://secwatch.observer/filing/0001493152-24-024108#claim-0866438761","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224024108/0001493152-24-024108-index.htm"},{"fact_type":"earnings_release","fact_key":"4daba0af2e9b816e9bdca59f61ade34be116c409","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":"$176,000"},"claim":"Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.","evidence_excerpt":"Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-019889","anchor_url":"https://secwatch.observer/filing/0001493152-24-019889#claim-4daba0af2e9b816e9bdca59f61ade34be116c409","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/0001493152-24-019889-index.htm"},{"fact_type":"earnings_release","fact_key":"ba7b25bad9b12b186ec0f1b1383447639461d67a","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-04-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"year ended December 31, 2023","report_date":"2024-04-12","result_type":"reported_results","revenue_text":"$1.5 million"},"claim":"Insight Molecular Diagnostics Inc. reported year ended December 31, 2023 results: revenue $1.5 million.","evidence_excerpt":"commercial and regulatory milestones.” 2023\nFourth Quarter and Full-Year Financial Results Net\nrevenue for the three months and year ended December 31, 2023, was $314,000 and $1.5 million, respectively, an increase of 15% compared\nto the fourth quarter 2022 and 57% compared to the full year 2022, due to increased revenue from Pharma Services. Cost\nof revenues for","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-014380","anchor_url":"https://secwatch.observer/filing/0001493152-24-014380#claim-ba7b25bad9b12b186ec0f1b1383447639461d67a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm"},{"fact_type":"material_agreement","fact_key":"d7d99eb62a96aa377316820af7651b7bc2859e7d","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-04-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain accredited investors","effective_date":"2024-04-11","item_codes_triggered":["1.01"],"value_text":"approximately $15.8 million"},"claim":"Insight Molecular Diagnostics Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $15.8 million (effective 2024-04-11).","evidence_excerpt":"On April 11, 2024, Oncocyte Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of an aggregate of 5,077,387 shares (the “Common Shares”) of common stock of the Company, no par value per share (the “Common Stock”), and pre-funded warrants (“Pre-Funded Warrants”) to purchase up to 342,888 shares of Common Stock, with an exercise price of $0.0001 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-014380","anchor_url":"https://secwatch.observer/filing/0001493152-24-014380#claim-d7d99eb62a96aa377316820af7651b7bc2859e7d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014380/0001493152-24-014380-index.htm"},{"fact_type":"material_agreement","fact_key":"02949f90ae1f24965f29b95aa20b483af3ed7d98","cik":1642380,"ticker":"IMDX","company_name":"Insight Molecular Diagnostics Inc.","filed_at":"2024-04-11T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Collaboration Agreement","agreement_type":"collaboration","counterparty":"Bio-Rad Laboratories, Inc.","effective_date":"2024-04-05","item_codes_triggered":["1.01"],"value_text":null},"claim":"Insight Molecular Diagnostics Inc. entered into Collaboration Agreement with Bio-Rad Laboratories, Inc. (effective 2024-04-05).","evidence_excerpt":"On April 5, 2024, Oncocyte Corporation (the “Company”) entered into a Collaboration Agreement with Bio-Rad Laboratories, Inc. (“Bio-Rad”) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents (the “Collaboration Agreement”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-014355","anchor_url":"https://secwatch.observer/filing/0001493152-24-014355#claim-02949f90ae1f24965f29b95aa20b483af3ed7d98","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224014355/0001493152-24-014355-index.htm"}]}